Inventiva S.A. (IVA)
| Market Cap | 733.72M +56.0% |
| Revenue (ttm) | 7.94M -52.0% |
| Net Income | -415.80M |
| EPS | -2.23 |
| Shares Out | 207.71M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,094,061 |
| Open | 3.670 |
| Previous Close | 3.710 |
| Day's Range | 3.460 - 3.690 |
| 52-Week Range | 2.854 - 7.983 |
| Beta | 0.88 |
| Analysts | Strong Buy |
| Price Target | 15.13 (+337.28%) |
| Earnings Date | Mar 30, 2026 |
About IVA
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-β, a pre-clinical program for the tr... [Read more]
Financial Performance
In 2025, Inventiva's revenue was 6.76 million, a decrease of -52.03% compared to the previous year's 14.10 million. Losses were -354.14 million, 92.2% more than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for IVA stock is "Strong Buy." The 12-month stock price target is $15.13, which is an increase of 337.28% from the latest price.
News
Claret Capital Partners participates in €130m financing for Inventiva
Claret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financing, to support its lead asset through Phase 3.
Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development
Claret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financing, to support its lead asset through Phase 3.
Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing
Daix (France), New York City (New York, United States), June 12, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Combined General Meeting of June 30, 2026 - Availability of the Preparatory Documents
Daix (France), New York City (New York, United States), June 9,2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on t...
Inventiva Transcript: Jefferies Global Healthcare Conference 2026
A recapitalized, single-asset company is advancing lanifibranor for F2/F3 MASH, with phase III top-line data expected in Q4 2024 and a commercial launch targeted for 2028. The product is positioned to compete strongly in diabetic and fibrosis-driven segments.
Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Inventiva Reports 2026 First Quarter Financial Information¹
Daix (France), New York City (New York, United States), May 26, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
Inventiva Earnings release: Q1 2026
Inventiva released its Q1 2026 earnings on May 25, 2026, summarizing the period's financial results.
Inventiva Earnings release: Q1 2026
Inventiva released its Q1 2026 earnings on May 25, 2026, summarizing the period's financial results.
Inventiva to Present at 2026 Jefferies Global Healthcare Conference
Daix (France), New York (United States), May 21, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development...
Inventiva to Present Abstracts at the EASL Congress 2026
Daix (France), New York City (New York, United States) , May 13, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused ...
Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor
Recruitment of Chief Financial Officer, Chief Legal Officer, and Chief People Officer reflects Inventiva's organizational build-out as it advances toward potential commercialization. Axel-Sven Malkome...
Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F
Daix (France), New York City (New York, United States), April 8, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developme...
Inventiva Earnings Call Transcript: Q4 2025
Inventiva completed NATiV3 phase III enrollment for lanifibranor in MASH, expects top-line data in Q4 2026, and is well-funded through key milestones. Strategic focus, leadership expansion, and divestment of odiparcil position the company for regulatory and commercial readiness.
Inventiva Annual report: Q4 2025
Inventiva has published its Q4 2025 annual report on March 31, 2026.
Inventiva Earnings release: Q4 2025
Inventiva released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Inventiva Earnings release: Q4 2025
Inventiva released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Inventiva Annual report: Q4 2025
Inventiva has published its Q4 2025 annual report on March 31, 2026.
Inventiva reports 2025 full year results and provides a business update
Daix (France), New York City (New York, United States), March 30, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developme...
Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results
Daix (France), New York (United States), March 23, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the developme...
Inventiva Transcript: Barclays 28th Annual Global Healthcare Conference
Lanifibranor's Phase III trial for MASH is well-powered and builds on strong Phase IIb results, targeting F2/F3 patients with a favorable safety profile and differentiated market positioning. The company plans independent commercialization, with a cash runway through Q3 2027.
Inventiva Transcript: Leerink Global Healthcare Conference 2026
Lanifibranor's phase 3 data for MASH is expected in late 2024, with strong phase 2b efficacy and a favorable safety profile. The program targets F2/F3 patients, especially diabetics, and plans for commercial launch and expanded indications are underway.
Inventiva Transcript: TD Cowen 46th Annual Health Care Conference
NATiV3 phase III trial targets strong dual endpoints in fibrosis and NASH resolution, with conservative powering and a readout expected this year. Safety profile is manageable, with modest weight gain and no major concerns. Strategy targets diabetic and non-diabetic NASH, with future trials for F4/cACLD and potential combination therapies.